AstraZeneca Plc said on Friday a late-stage study showed its top-selling drug, Tagrisso, had significantly helped patients with a type of lung cancer live longer without the disease worsening.
Original Article: AstraZeneca's Tagrisso helps lung cancer patients live longer: study